May 6th 2024
Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Combining and Sequencing Agents with Immunotherapies in Prostate Cancer
April 23rd 2014Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.
Watch
HDAC/mTOR Inhibitor Combination as Treatment for Prostate Cancer
April 8th 2014Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.
Watch
The Efficacy of Tasquinimod in Men with mCRPC
March 28th 2014Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer
Watch
Developing Next-Generation Anti-Androgen Therapies for CRPC
March 21st 2014Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer
Watch
The Benefit of Radiotherapy/Antiandrogen Combination in Men With Locally Advanced Prostate Cancer
February 18th 2014Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, comments on the benefit of radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.
Watch
Evaluating Tumor-Directed PET Imaging of mCRPC Bone Metastases Using Zr-89-J591
February 7th 2014Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.
Watch
A Biomarker Development Trial of Satraplatin in Patients With mCRPC
February 1st 2014William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Read More
Safety of Radium-223 in mCRPC Endures in Extended Follow-up
January 31st 2014Patients with bone metastatic castration-resistant prostate cancer (CRPC) who received radium-223 dichloride (Xofigo) continued to have a low incidence of myelosuppression and no associated secondary malignancies at a 1.5-year follow-up of the pivotal phase III ALSYMPCA study that was presented at the 2014 Genitourinary Cancers Symposium.
Read More
Abiraterone and Enzalutamide for mCRPC
January 31st 2014Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.
Read More
Benefit for Radiotherapy/ Antiandrogen Combination Reinforced by Long-Term Data
January 30th 2014Improved outcomes continued to be demonstrated with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer, according to an updated analysis, conducted after 11 years of observation.
Read More